

Henry Schein Dental to be Sales Agent and Exclusive Distributor of OraPharma's Arestin®

April 23, 2008

Henry Schein Dental to be Sales Agent and Exclusive Distributor of OraPharma's Arestin®

Relationship extends offering of leading periodontal treatment

MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (NASDAQ: HSI), the largest distributor of healthcare products and services to office-based practitioners in the combined North American and European markets, today announced that Henry Schein Dental and OraPharma, Inc., a Johnson & Johnson Company, have entered into a relationship that will extend the offering of ARESTIN®, the first locally administered, time-released antibiotic encapsulated in microspheres that effectively kills the germs that cause periodontal disease or periodontitis. Through this agreement, Henry Schein Dental will serve as sales agent and exclusive distributor of ARESTIN® in the United States.

"This is an exciting alliance that provides Henry Schein Dental with a significant offering in an important new market for our Company," said Tim Sullivan, President of Henry Schein Dental. "Our goal is to provide 'everything dental' to our customers, and the addition of ARESTIN to our offering certainly furthers that mission. ARESTIN provides unique benefits for treating a condition that affects millions of Americans. We see great potential for the adoption of ARESTIN by our U.S. Dental customers, in addition to periodontists, and we look forward to collaborating with OraPharma's field representatives as we grow ARESTIN's market share in this country."

Currently, more than one in three Americans over age 30 has some form of periodontal disease, according to the American Academy of Periodontology. Research shows that untreated periodontal infections may contribute to systemic health problems, including cardiovascular disease.

In addition, according to the Academy of General Dentistry, every \$1 spent on preventative oral care results in an \$8-\$10 savings in subsequent restorative services.

About Henry Schein

Henry Schein, a Fortune 500® company and a member of the NASDAQ 100® Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups – Dental, Medical, International and Technology – serve more than 550,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions.

The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as Aruba®, the Company's electronic catalog and ordering system. Its leading practice-management software solutions have a user base of more than 52,000 practices, including DENTRIX®, Easy Dental®, Oasis® and EXACT® for dental practices, MicroMD® for physician practices, and AVImark® for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs over 12,000 people and has operations or affiliates in 20 countries. The Company's net sales reached a record \$5.9 billion in 2007. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

Contacts

Henry Schein, Inc.

Steven Paladino, 631-843-5500
Executive Vice President and Chief Financial Officer
steven.paladino@henryschein.com

or

Investors:

Neal Goldner, 631-845-2820
Vice President, Investor Relations
neal.goldner@henryschein.com

or

Media:

Susan Vassallo, 631-843-5562
Vice President, Corporate Communications
susan.vassallo@henryschein.com